whitepaper
Handbook: Advanced flow cytometry handbook
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
List view / Grid view
In Vitro
news
New bacterial protein found to improve mitochondrial function
Protein released by C. burnetti interacts with antioxidising enzyme GPX4 to prevent cell damage and death.
article
Protein offers promise for treatment of reproductive conditions
Scientists found that CXCR4 protein expression outside of the uterus is important for pregnancy maintenance.
news
Intratumoural bacteria drives radiation therapy resistance
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
webinar
Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
20 October 2023 | By Eurofins Discovery
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
article
Human neuronal cells: possibilities in drug safety testing
Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. These cells demonstrate considerable promise for uncovering drug-induced perturbations to…
news
Engineered immune cells for improved cancer defence
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
news
Japanese squirrels develop human hereditary diseases with ageing
Researchers at Tokyo University of Agriculture and Technology, led by Dr Tomoaki Murakami, have uncovered a previously undocumented disease, fibrinogen Aα-chain amyloidosis, highly prevalent in Japanese squirrels, shedding light on its parallels with the human condition. Their findings offer new insights into amyloidosis and its potential implications for medical research.
webinar
SH2 domains as a target class in cancer and inflammation
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
article
Exploring alternatives to animal testing in drug discovery
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
article
The promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
article
Advancing directed protein evolution technology
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
news
Genome-edited iPSCs show promise for treating Fabry Disease
Japanese researchers successfully engineered iPSCs to secrete a modified enzyme, mNAGA, and restored enzyme activity in vitro and in a mouse model, opening new avenues for regenerative medicine for conditions such as Fabry Disease.
whitepaper
ebook: Fluorescence polarization assays
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
webinar
Cardiac and vascular safety liabilities using totality of evidence approach
27 June 2023 | By Eurofins Discovery
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.
